Aurinia Pharmaceuticals (AUPH) Total Current Liabilities (2016 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Total Current Liabilities of $86.6 million for Q1 2026, down 7.65% on a QoQ basis from $93.7 million in Q4 2025, and up 26.53% year-over-year from $68.4 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Total Current Liabilities (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Total Current Liabilities history runs 11 years deep, the most recent figure standing at $86.6 million for Q1 2026.
- Quarterly Total Current Liabilities rose 26.53% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (up 26.53% YoY) and the FY2025 annual result came in at $93.7 million, down 4.13% from the prior year.
- Total Current Liabilities was $86.6 million for Q1 2026 at Aurinia Pharmaceuticals, down from $93.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $97.8 million in Q4 2024 and bottomed at $33.8 million in Q1 2022.
- A 5-year average of $67.0 million and a median of $73.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 78.08% — and 2025, when it retreated 4.13%.
- Aurinia Pharmaceuticals' Total Current Liabilities stood at $46.1 million in 2022, then jumped by 67.41% to $77.2 million in 2023, then climbed by 26.66% to $97.8 million in 2024, then declined by 4.13% to $93.7 million in 2025, then slipped by 7.65% to $86.6 million in 2026.
- Business Quant data shows AUPH's Total Current Liabilities at $86.6 million in Q1 2026, $93.7 million in Q4 2025, and $76.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 86.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.56 Mn |
| Dec 31, 2025 | 93.72 Mn |
| Sep 30, 2025 | 76.22 Mn |
| Jun 30, 2025 | 78.27 Mn |
| Mar 31, 2025 | 68.41 Mn |
| Dec 31, 2024 | 97.76 Mn |
| Sep 30, 2024 | 78.61 Mn |
| Jun 30, 2024 | 76.90 Mn |
| Mar 31, 2024 | 71.05 Mn |
| Dec 31, 2023 | 77.19 Mn |
| Sep 30, 2023 | 73.89 Mn |
| Jun 30, 2023 | 61.66 Mn |
| Mar 31, 2023 | 42.05 Mn |
| Dec 31, 2022 | 46.11 Mn |
| Sep 30, 2022 | 41.77 Mn |
| Jun 30, 2022 | 34.63 Mn |
| Mar 31, 2022 | 33.84 Mn |
| Dec 31, 2021 | 40.65 Mn |
| Sep 30, 2021 | 37.54 Mn |
| Jun 30, 2021 | 29.32 Mn |